WGRX
Wellgistics Health, Inc. Common StockWGRX
WGRX
About: Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
–
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for WGRX.
Financial journalist opinion
Based on 4 articles about WGRX published over the past 30 days
Neutral
Accesswire
10 hours ago
Wellgistics Health Reports Strong Q1 Operational Growth Across Manufacturer, Product, and Pharmacy Expansion with Over 350 New Pharmacies Added to Its Nationwide Network
TAMPA, FL / ACCESS Newswire / April 30, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced key unaudited operational performance highlights for the first quarter of 2025, signaling continued acceleration across its national platform. Some of Wellgistics Health's Q1 2025 operational highlights include: 354 new independent pharmacies added 22 new pharmaceutical manufacturers onboarded 57 new prescription drug products integrated into the portfolio "These numbers are a clear signal the industry is demanding change," said Brian Norton, CEO of Wellgistics Health.
Neutral
Accesswire
6 days ago
Wellgistics Names Mark DiSiena as New CFO
TAMPA, FL / ACCESS Newswire / April 24, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced a key leadership change to propel Wellgistics Health's strategic growth initiatives forward by appointing Mark DiSiena as its new Chief Financial Officer. As the new Chief Financial Officer of Wellgistics, Mr.
Neutral
Accesswire
2 weeks ago
CEO of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price
TAMPA, FL / ACCESS Newswire / April 15, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that it has entered into an amendment to the Membership Interest Purchase Agreement with Wellgistics LLC and Wellgistics LLC's former owners to convert a significant cash payment owed by the Company into shares of the Company's common stock at the initial public offering price of $4.50 per share. Specifically, the Company has converted $1.5 million in debt that the Company owed to a seller entity controlled by Brian Norton, its Chief Executive Officer, and that the Company would have needed to pay by June 14, 2025.
Neutral
Accesswire
2 weeks ago
Wellgistics Health, Inc. Announces Agreement to Acquire Peek Healthcare Technologies, Inc., to Support Over 2,500 Patients and $1.5MM Annual Revenue
TAMPA, FL / ACCESS Newswire / April 10, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced it has entered into a definitive agreement to acquire Peek Healthcare Technologies, Inc. ("Peek"). Peek operates the Peek Meds Marketplace, a digital prescription shopping platform built to empower consumers with real-time pricing transparency to assist consumers with making more informed medication purchase decisions.
Neutral
GlobeNewsWire
1 month ago
Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics Health”), a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance. This milestone validates that Wellgistics Health meets the industry's highest standards for security, availability, processing integrity, confidentiality, and privacy, reinforcing its commitment to data protection and regulatory compliance.
Neutral
GlobeNewsWire
1 month ago
Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure
TAMPA, FL, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (the “Company”), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that Tim Canning, Chief Executive Officer, will be departing the company. Mr. Canning's leadership tenure helped guide Wellgistics Health through pivotal phases, and the Company expresses gratitude for his contributions.
Neutral
GlobeNewsWire
1 month ago
Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond ™ , is designed to provide multiple levels of protection
Neutral
GlobeNewsWire
2 months ago
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo's emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo's first marketed product is Galectovid™, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Further details on Galectovid™ are available at www.galectovid.com .
Neutral
GlobeNewsWire
2 months ago
Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering
Tampa, Florida, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 shares of its common stock at a public offering price of $4.50 per share. The shares have been approved for listing on the Nasdaq Capital Market and commenced trading on February 21, 2025, under the ticker symbol "WGRX."
Neutral
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.
Charts implemented using Lightweight Charts™